Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key.
crizotinib
gastrointestinal stromal tumor (GIST)
imatinib
lung cancer
osimertinib
therapeutic drug monitoring
tyrosine kinase inhibitor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
18
02
2023
revised:
03
03
2023
accepted:
05
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
A combination of tyrosine kinase inhibitors (TKIs) is likely to be a therapeutic option for numerous oncological situations due to high frequency of oncogenic addiction and progress in precision oncology. Non-small cell lung cancer (NSCLC) represents a subtype of tumors for which oncogenic drivers are frequently involved. To the best of our knowledge, we report the first case of a patient treated with three different TKIs. Osimertinib and crizotinib were administered concurrently for an epidermal growth factor receptor (
Identifiants
pubmed: 36982592
pii: ijms24065518
doi: 10.3390/ijms24065518
pmc: PMC10054357
pii:
doi:
Substances chimiques
osimertinib
3C06JJ0Z2O
Crizotinib
53AH36668S
Tyrosine Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Protein Kinase Inhibitors
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
Cancers (Basel). 2020 May 08;12(5):
pubmed: 32397295
J Hematol Oncol. 2022 Oct 8;15(1):143
pubmed: 36209184
Ann Oncol. 2022 Oct;33(10):1071-1082
pubmed: 35777707
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
Drug Des Devel Ther. 2020 Apr 30;14:1663-1681
pubmed: 32431491
J Thorac Oncol. 2018 Nov;13(11):e232-e234
pubmed: 30368417
World J Surg Oncol. 2020 May 6;18(1):88
pubmed: 32375797
Cancers (Basel). 2022 Apr 12;14(8):
pubmed: 35454838
Future Oncol. 2022 Mar;18(9):1039-1054
pubmed: 34918545
Ann Oncol. 2013 Apr;24(4):1087-93
pubmed: 23175622
J Transl Med. 2019 Feb 21;17(1):52
pubmed: 30791921
Pharmaceutics. 2022 Sep 01;14(9):
pubmed: 36145591
J Hematol Oncol. 2020 Oct 27;13(1):143
pubmed: 33109256
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Expert Rev Anticancer Ther. 2022 Oct;22(10):1115-1125
pubmed: 35993098
Curr Treat Options Oncol. 2022 Nov;23(11):1626-1644
pubmed: 36242712
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Clin Pharmacol Ther. 2021 Feb;109(2):394-402
pubmed: 32686074
Mol Cancer. 2018 Feb 19;17(1):58
pubmed: 29455648
Clin Cancer Res. 2002 Oct;8(10):3034-8
pubmed: 12374669
Cancers (Basel). 2021 Jul 09;13(14):
pubmed: 34298655
Pharmaceutics. 2022 Nov 17;14(11):
pubmed: 36432682
Eur J Cancer. 2014 Aug;50(12):2020-36
pubmed: 24928190